Creo Medical Group annual ebitda
2022
2023
2024
2025
Creo Medical Group EBITDA Growth & History (CREO)
Creo Medical Group's calculated EBITDA was −£16.2M for fiscal 2025.
View full Creo Medical Group company overviewCreo Medical Group annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£16.2M | £9.9M | — |
| 2024 | 2024-12-31 | −£26.1M | −£3.3M | — |
| 2023 | 2023-12-31 | −£22.8M | £4.7M | — |
| 2022 | 2022-12-31 | −£27.5M | — | — |
Creo Medical Group ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Creo Medical Group's ebitda increased from −£27.5M to −£16.2M, a change of £11.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Creo Medical Group source filings ↗Community posts
Creo Medical narrows operating loss as device revenue rises 45%
Creo Medical ($CREO) increased first-half revenue to £3.2 million from £2.2 million and reduced its underlying continuing operating loss to £4.9 million from £6.7 million. Underlying operating costs fell 15% to £7.9 million as the surgical- ...
